Scleromyxedema and the dermato-neuro syndrome: Case report and review of the literature

Journal of Cutaneous Pathology

Volumn 39, Issue 5, 2012, Pages 508-517

  Fleming, Kirsten E ^a   Virmani, Divya ^b   Sutton, Evelyn ^c   Langley, Richard ^c   Corbin, Jessica ^c   Pasternak, Sylvia ^a   Walsh, Noreen M ^a  

^a Capital District Health Authority   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

dermato neuro syndrome; lichen myxedematosus; nephrogenic systemic fibrosis; papular mucinosis; scleromyxedema

Indexed keywords

MUCIN;

CASE REPORT; CELL PROLIFERATION; COMA; DERMIS; FEMALE; FIBROBLAST; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; REVIEW; SCLEROMYXEDEMA; SEIZURE; SYNDROME;

CELL PROLIFERATION; COMA; DERMIS; FEMALE; FIBROBLASTS; HUMANS; MIDDLE AGED; MUCINS; SCLEROMYXEDEMA; SEIZURES; SYNDROME;

EID: 84860127215     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2012.01882.x     Document Type: Review

References (44)

1. Rongioletti F, Rebora A., Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44: 273.
2. Gabriel SE, Perry HO, Oleson GB, Bowles CA., Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine 1988; 67: 58.
3. Dinneen AM, Dicken CH., Scleromyxedema. J Am Acad Dermatol 1995; 33: 37.
4. Weedon D., Weedon's skin pathology, 3rd ed. London: Elsevier, 2011; 355.
5. Kantor GR, Bergfeld WF, Katzin WE, et al., Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol 1986; 14: 879.
6. Blum M, Wigley FM, Hummers LK., Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 2008; 87: 10.
7. Pomann JJ, Rudner EJ., Scleromyxedema revisited. Int J Dermatol 2003; 42: 31.
8. Webster GF, Matsuoka LY, Burchmore D., The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 1993; 28: 105.
9. Berger JR, Dobbs MR, Terhune MH, Maragos WF., The neurologic complications of scleromyxedema. Medicine 2001; 80: 313.
10. River Y, Levy I, Gilead L, Orbach H, Almog Y., Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome". Neurology 1996; 46: 1778.
11. Ulrich M, Roewert-Huber J, Gonzalez S, Rius-Diaz F, Stockfleth E, Kanitakis J., Peritumoral clefting in basal cell carcinoma: correlation of in vivo reflectance confocal microscopy and routine histology. J Cutan Pathol 2011; 38: 190.
12. Harris RB, Perry HO, Kyle RA, Winkelmann RK., Treatment of scleromyxedema with melphalan. Arch Dermatol 1979; 115: 295.
13. Findlay GH, Simson IW., Scleromyxoedema. S Afr Med J 1960; 34: 69.
14. Lai a Fat RFM, Suurmond D, Radl J, van Furth R., Scleromyxedema (lichen myxedematosus) associated with a paraprotein, IgG of type kappa. Br J Dermatol 1973; 88: 107.
15. Harper RA, Rispler J., Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978; 199: 545.
16. Ferrarini M, Helfrich DJ, Walker ER, Medsger TA Jr, Whiteside TL., Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989; 16: 837.
17. Yaron M, Yaron I, Yust I, Brenner S., Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985; 12: 171.
18. Bata-Csorgo Z, Husz S, Foldes M, et al., Scleromyxedema. J Am Acad Dermatol 1999; 40: 343.
19. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE., Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000: 356: 1000.
20. Cowper SE., Gadolinium-is it to blame? J Cutan Pathol 2008; 35: 520.
21. Kucher C, Xu X, Pasha T, Elenitsas R., Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 2005; 32: 484.
22. Satter EK, Metcalf JS, Maize JC., Can scleromyxedema be differentiated from nephrogenic fibrosing dermopathy by the distribution of the infiltrate? J Cutan Pathol 2006; 33: 756.
23. Basak P, Jesmajian S., Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011; 56: 59.
24. McCuistion CH, Schoch EP., Autopsy findings in lichen myxedematosus. AMA Arch Derm 1956; 74: 259.
25. Godby A, Bergstresser PR, Chaker B, Pandya AG., Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 1998; 38: 289.
26. Farmer ER, Hambrick GW, Shulman LE., Papular mucinosis: a clinicopathologic study of four patients. Arch Dermatol 1982; 118: 9.
27. Milam CP, Cohen LE, Fenske NA, Ling NS., Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988; 19: 469.
28. Johkura K, Susuki K, Hasegawa O, Kuroiwa Y, Komatsumoto S., Encephalopathy in scleromyxedema. Neurology 1999; 53: 1138.
29. Marshall K, Klepeiss SA, Ioffreda MD, Helm KF., Scleromyxedema presenting with neurologic symptoms: a case report and review of the literature. Cutis 2010; 85: 137.
30. Rudner EJ, Mehregan A, Pinkus H., Scleromyxedema. A variant of lichen myxedematosus. Arch Dermatol 1966; 93: 3.
31. Ochitill HN, Amberson J., Acute cerebral symptomatology, a rare presentation of scleromyxedema. J Clin Psychiatry 1978: 39: 471.
32. Reid TL, Spoto DV, Larrabee GJ, Shlamowitz MA, Horowitz SA., Monoclonal paraproteinemia with subacute encephalopathy, seizures, and scleromyxedema. Neurology 1987: 37: 1054.
33. Lister RK, Jolles S, Whittaker S, et al., Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000; 43: 403.
34. Gonzalez J, Palangio M, Schwartz J, Klainer AS, Bisaccia E., Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol 2000; 42: 927.
35. Gholam P, Hartmann M, Enk A., Arndt-Gottron scleromyxedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 2007; 157: 1040.
36. Rodrigues M, Machado A, Ventura F, Duarte ML, Ferreira C., Scleromyxedema diagnosis following unexplained encephalopathy. Eur J Dermatol 2008: 18: 78.
37. Rey JB, Luria RB., Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 2009; 60: 1037.
38. Tan E, Lau N, Yung A., Scleromyxoedema: a cause for unexplained encephalopathy and myositis. Clin Exp Dermatol 2010; 35: 746.
39. do Prado AD, Schmoeller D, Bisi MC, Piovesan DM, Dias FS, Staub HL., Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis. Int J Dermatol 2011 [Epub 15 June 2011].
40. Fett NM, Toporcer MB, Dalmau J, Shinohara MM, Vogl DT., Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011; 86: 893.
41. Bonnetblanc JM, Bedane C., Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up. Arch Dermatol 1991; 127: 1733.
42. Shergill B, Orteu CH, McBride SR, Rustin MHA., Dementia associated with scleromyxedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol 2005; 153: 650.
43. Jolles S, Hughes J., Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int Immunopharmacol 2006; 6: 579.
44. Hamrock DJ., Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006: 6: 535.